Search results
Results from the WOW.Com Content Network
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane. Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
Side effects of diabetes medications can include weight loss. Beyond taking your diabetes medications as directed, you might need to make lifestyle changes after a diabetes diagnosis.
Mild symptoms such as nausea, loss of appetite, dizziness, vomiting, headache, sore gums, or frequent urination are common with this medication. Life-threatening side effects such as thrombocytopenia, hemolytic anemia, leukemia and encephalopathy are extremely rare. [4] Theoretically probenecid can increase the risk of uric acid kidney stones.
In the colon, bacteria will digest the complex carbohydrates, thereby causing gastrointestinal side effects such as flatulence and diarrhea. Since these effects are dose-related, it is generally advised to start with a low dose and gradually increase the dose to the desired amount. Pneumatosis cystoides intestinalis is another reported side ...
Behind the counter at your local gas station, convenience store, or bodega, tucked within the energy shots and flavored cigarillos, are a variety of male enhancement products like Rhino pills. You ...
Knowing your blood sugar status is crucial when you have diabetes — and over 17,000 shoppers trust this kit. Amazon's No. 1 bestselling diabetes testing kit is now $26 — but only with this ...
The FDA approved the drug on January 29, 1997, and it appeared in pharmacies in late March. At the time, Dr. Solomon Sobel, a director at the FDA overseeing diabetes drugs, said in a New York Times interview that adverse effects of troglitazone appeared to be rare and relatively mild. [13]
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to Thiazolidinedione for treatment of type 2 diabetes. [26]